Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report

Afsaneh Shirani; Scott R Dalton; Eric J Avery; Lakshman Arcot Jayagopal; Christina Meyer; Olaf Stuve; Rana Zabad

doi:10.1177/11795735211053784

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report

J Cent Nerv Syst Dis. 2021 Nov 20:13:11795735211053784. doi: 10.1177/11795735211053784. eCollection 2021.

Authors

Afsaneh Shirani¹, Scott R Dalton², Eric J Avery³, Lakshman Arcot Jayagopal¹, Christina Meyer⁴, Olaf Stuve⁵, Rana Zabad¹

Affiliations

¹ Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
² Sagis Dermatopathology, Houston, TX, USA.
³ Nebraska Hematology Oncology, Lincoln, NE, USA.
⁴ Dermatology Associates of Lincoln, Lincoln, NE, USA.
⁵ Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX; VA North Texas Health Care System, Dallas VA Medical Center, Dallas, TX, USA.

Abstract

A 48-year-old Caucasian woman with history of multiple sclerosis (MS) presented with erythematous papulonodular lesions in her extremities and trunk. She was being treated with glatiramer acetate (GA) for the past 10 years and the glatiramoid, Glatopa, for 2 years prior to this presentation. A skin biopsy showed CD30⁺ lymphoproliferative disorder consistent with lymphomatoid papulosis (LyP). Three weeks after stopping Glatopa, her skin lesions were improved. It remains unclear whether GA's or Glatopa's capability to alter T-cell differentiation, may have a link with LyP. This case report is a reminder to be vigilant for skin lesions in patients with MS.

Keywords: Lymphomatoid papulosis; glatiramer acetate; glatiramoids; glatopa; multiple sclerosis; skin.

Publication types

Case Reports